Vor Biopharma Q3 net loss widens on higher expenses
VOR•Vor Biopharma reported a third-quarter net loss of $86.7 million, missing analyst expectations of $47.19 million. Higher research and development and general and administrative expenses reflected expanded clinical programs and increased headcount.
1. Quarterly results
Vor Biopharma’s third-quarter net loss widened to $86.7 million, compared with analyst expectations for a loss of $47.19 million. The company said higher research and development expenses reflected new clinical programs for telitacicept in generalized myasthenia gravis and primary Sjögren’s disease; higher general and administrative expenses reflected increased personnel and stock-based compensation.
2. Trial outlook
The company completed enrollment in its Phase 3 UPSTREAM MG trial for generalized myasthenia gravis and expects topline results in the first half of 2027. It plans to begin dosing the first patient in its Phase 3 UPSTREAM oMG trial in the first half of 2027, and expects its cash and investments to fund operations into early 2029.
